Pharma Equity Group Income Statement

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	10.73	12.29	11.81	5.78
Research & Development	7.44	9	8.82	5.5
Operating Expenses	18.17	21.29	25.03	11.28
Operating Income	-18.17	-21.29	-25.03	-11.28
Interest Expense	-4.16	-4.96	-1.56	-0.02
Interest & Investment Income	0.02	0.01	0.01	-
Currency Exchange Gain (Loss)	-0	-0	-	-
Other Non Operating Income (Expenses)	-	-0	-	-
Pretax Income	-22.31	-26.24	-26.58	-11.3
Income Tax Expense	-1.3	-1.82	-2.23	-1.86
Net Income	-21.02	-24.42	-24.35	-9.44
Net Income to Common	-21.02	-24.42	-24.35	-9.44
Shares Outstanding (Basic)	1,068	1,068	1,080	954
Shares Outstanding (Diluted)	1,068	1,077	1,089	977
Shares Change (YoY)	-2.29%	-1.10%	11.38%	-
EPS (Basic)	-0.02	-0.02	-0.02	-0.01
EPS (Diluted)	-0.02	-0.02	-0.02	-0.01
Free Cash Flow	-22.92	-22.86	-16.7	-8.3
Free Cash Flow Per Share	-0.02	-0.02	-0.01	-0.01
EBITDA	-18.14	-21.27	-25.01	-11.02
D&A For EBITDA	0.03	0.02	0.02	0.26
EBIT	-18.17	-21.29	-25.03	-11.28

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.